Page 8 - Processa Pharmaceuticals News Today

Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality […]

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 93,000 shares, a drop of 18.6% from the February 13th total of 114,300 shares. Based on an average trading volume of 36,300 shares, the short-interest ratio is presently 2.6 days. […]

HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company...

Epilepsy Pipeline Analysis: 70+ Key Pipeline Therapies and 70+ Key Pharma Players are Looking Out in the Epilepsy Pipeline Landscape

Epilepsy Pipeline Analysis: 70+ Key Pipeline Therapies and 70+ Key Pharma Players are Looking Out in the Epilepsy Pipeline Landscape

  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of ...

NKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch KENILWORTH (NJ) (dpa-AFX) - Todays Daily Dose brings you news about Nektars collaboration with Merck; Pfizer initiating a refractory multiple myeloma study; Processa Pharmas strategic financing; and vTv Therapeutics initiation of a phase 1 multiple ascending dose study of HPP737. Read on... 1. Nektar Teams Up With Merck Nektar Therapeutics (NKTR) has entered into a clinical trial collaboration and supply agreement w...

Toward the end of trading Wednesday, the Dow traded up 0.11% to 31,556.47 while the NASDAQ fell 0.89% to 13,921.94. The S&P also fell, dropping 0.27% to ...